

# Claudio Cerchione

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6752147/publications.pdf>

Version: 2024-02-01

139  
papers

1,442  
citations

516710

16  
h-index

552781

26  
g-index

143  
all docs

143  
docs citations

143  
times ranked

2424  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	5.3	6
2	Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes. <i>Supportive Care in Cancer</i> , 2022, 30, 2293-2298.	2.2	6
3	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 820768.	2.8	5
4	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. <i>Cancers</i> , 2022, 14, 1173.	3.7	4
5	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	1.7	6
6	Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20002-e20002.	1.6	0
7	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	3.7	0
8	Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7042-7042.	1.6	0
9	Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. <i>Hematological Oncology</i> , 2022, 40, 987-998.	1.7	5
10	Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. <i>Journal of Medical Virology</i> , 2021, 93, 124-126.	5.0	18
11	Correspondence in reference to previously published manuscript: Faouzi Djebbari et al. Efficacy and infection morbidity of frontline immunochemotherapy in follicular lymphoma. <i>Eur J Haematol</i> . 2020; 105: 667-671. <i>European Journal of Haematology</i> , 2021, 106, 734-736.	2.2	2
12	Multiple myeloma in 2020: state of the art. <i>Panminerva Medica</i> , 2021, 62, 191-192.	0.8	0
13	Current and future perspectives of maintenance therapy in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 225-233.	0.8	1
14	Old and new generation immunomodulatory drugs in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 207-219.	0.8	4
15	Urinary Biomarkers in Tumors: An Overview. <i>Methods in Molecular Biology</i> , 2021, 2292, 3-15.	0.9	6
16	Old and new generation proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 193-206.	0.8	6
17	Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 13-20.	0.8	1
18	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. <i>Panminerva Medica</i> , 2021, 63, 1-6.	0.8	5
20	Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. <i>PLoS ONE</i> , 2021, 16, e0247093.	2.5	5
21	BCMA-targeting approaches for treatment of multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 28-36.	0.8	4
22	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2150.	4.1	60
23	Chemotherapy-based regimens in multiple myeloma in 2020. <i>Panminerva Medica</i> , 2021, 63, 7-12.	0.8	10
24	Monoclonal antibodies in multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 21-27.	0.8	11
25	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	2.8	39
26	Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 657191.	2.8	17
27	Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 632231.	2.8	8
28	The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 791-799.	2.4	3
29	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. <i>Frontiers in Oncology</i> , 2021, 11, 643490.	2.8	12
30	PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. <i>Annals of Hematology</i> , 2021, 100, 1525-1535.	1.8	7
31	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2639.	3.7	17
32	Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 6973-6980.	2.2	1
33	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
34	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684396.	2.8	6
35	Safety of FLT3 inhibitors in patients with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 851-865.	2.2	17
36	Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. <i>Cancers</i> , 2021, 13, 4566.	3.7	10

#	ARTICLE	IF	CITATIONS
37	Autologous stem cell transplantation in multiple myeloma. Panminerva Medica, 2021, 62, 220-224.	0.8	7
38	Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?. Panminerva Medica, 2021, 62, 234-243.	0.8	3
39	Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma. Blood, 2021, 138, 4497-4497.	1.4	0
40	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. Blood, 2021, 138, 5020-5020.	1.4	0
41	An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. Anti-Cancer Drugs, 2020, 31, 67-72.	1.4	1
42	Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows. Hematology Reports, 2020, 12, 8950.	0.8	7
43	How We Manage Smoldering Multiple Myeloma. Hematology Reports, 2020, 12, 8951.	0.8	2
44	How I manage frontline transplant-eligible multiple myeloma in Italy. Hematology Reports, 2020, 12, 8954.	0.8	0
45	How I Treat Relapsed and/or Refractory Multiple Myeloma. Hematology Reports, 2020, 12, 8955.	0.8	4
46	Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. Frontiers in Oncology, 2020, 10, 592487.	2.8	7
47	ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients. Cell Transplantation, 2020, 29, 096368972096874.	2.5	26
48	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?. Medicine (United States), 2020, 99, e21440.	1.0	1
49	How I Manage Frontline Transplant-Ineligible Multiple Myeloma. Hematology Reports, 2020, 12, 8956.	0.8	6
50	A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. Journal of Hematology and Oncology, 2020, 13, 126.	17.0	135
51	What Influences the Choice of Ibrutinib vs Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?. Cell Transplantation, 2020, 29, 096368972095020.	2.5	0
52	Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells, 2020, 9, 2666.	4.1	11
53	Hydroxychloroquine as Prophylaxis for COVID-19: A Review. Frontiers in Pharmacology, 2020, 11, 605185.	3.5	10
54	MM-385: Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S310.	0.4	0

#	ARTICLE	IF	CITATIONS
55	MM-390: Pegfilgrastim vs. Filgrastim in the Supportive Care of Heavily Pre-Treated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S311-S312.	0.4	0
56	MDS-391: Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S324-S325.	0.4	0
57	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	4.1	6
58	KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. <i>Annals of Hematology</i> , 2020, 99, 2903-2909.	1.8	12
59	Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 395.	2.4	4
60	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17
61	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	3.7	19
62	PET/CT in Multiple Myeloma: Beyond FDG. <i>Frontiers in Oncology</i> , 2020, 10, 622501.	2.8	24
63	Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 624661.	2.8	35
64	Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. <i>Frontiers in Oncology</i> , 2020, 10, 624573.	2.8	5
65	Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic. <i>Insights Into Imaging</i> , 2020, 11, 129.	3.4	6
66	FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. <i>Minerva Medica</i> , 2020, 111, 427-442.	0.9	14
67	Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. <i>Minerva Medica</i> , 2020, 111, 386-394.	0.9	5
68	CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. <i>Minerva Medica</i> , 2020, 111, 455-466.	0.9	10
69	Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future. <i>Minerva Medica</i> , 2020, 111, 395-410.	0.9	10
70	Enasidenib and ivosidenib in AML. <i>Minerva Medica</i> , 2020, 111, 411-426.	0.9	20
71	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. <i>Minerva Medica</i> , 2020, 111, 478-490.	0.9	4
72	The Molecular Pathogenesis of Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 9054.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era.. Journal of Clinical Oncology, 2020, 38, e20517-e20517.	1.6	0
74	Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone.. Journal of Clinical Oncology, 2020, 38, e20514-e20514.	1.6	1
75	Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. Minerva Medica, 2020, 111, 467-477.	0.9	8
76	Acute leukemias in 2020: state of the art. Minerva Medica, 2020, 111, 384-385.	0.9	2
77	A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML) Tj ETQq1 1 0.784314 rgBT /Overlooked Clinical Practice. Blood, 2020, 136, 32-34.	1.4	0
78	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era. Blood, 2020, 136, 2-3.	1.4	0
79	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. Blood, 2020, 136, 2-2.	1.4	0
80	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. Blood, 2020, 136, 18-18.	1.4	0
81	Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients. Blood, 2020, 136, 37-38.	1.4	0
82	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. Blood, 2020, 136, 1-1.	1.4	0
83	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
84	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e358.	0.4	0
85	Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignanciesâ€”bendamustine and G-CSF support. Supportive Care in Cancer, 2019, 27, 1587-1588.	2.2	10
86	Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. Cancer Medicine, 2019, 8, 2802-2809.	2.8	7
87	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in Novel Agents' Era. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e359-e360.	0.4	0
88	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e358-e359.	0.4	0
89	A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e184-e194.	0.4	22
90	Abstract 2651: Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
91	Abstract 5279: Metabolic profiling defines a new characterization of acute myeloid leukemia and identifies NPM1-mutated cases as a distinct subgroup. , 2019, , .		1
92	ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. Blood, 2019, 134, 1565-1565.	1.4	1
93	Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.. Journal of Clinical Oncology, 2019, 37, e19522-e19522.	1.6	1
94	Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.. Journal of Clinical Oncology, 2019, 37, e18522-e18522.	1.6	0
95	Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy.. Journal of Clinical Oncology, 2019, 37, e18313-e18313.	1.6	1
96	Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model. Blood, 2019, 134, 2235-2235.	1.4	0
97	Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. , 2019, , .		0
98	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Annals of Hematology, 2018, 97, 1009-1018.	1.8	44
99	Lenalidomide at the dose of 25â€‰mg every other day in patients affected by multiple myeloma and renal failure. Anti-Cancer Drugs, 2018, 29, 371-372.	1.4	0
100	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Oncologist, 2018, 23, 454-460.	3.7	22
101	Safety and comfort of domestic bortezomib injection in real-life experience. Supportive Care in Cancer, 2018, 26, 3111-3116.	2.2	2
102	Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3-Î²-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography. Supportive Care in Cancer, 2018, 26, 1691-1694.	2.2	3
103	Rituximab in a riskâ€‰adapted treatment strategy gives excellent therapeutic results in nodular lymphocyteâ€‰predominant Hodgkin lymphoma. British Journal of Haematology, 2018, 182, 715-718.	2.5	4
104	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S256.	0.4	0
105	Combined Oral Administration of Analgesia and Anxiolysis for Pain Associated with Bone Marrow Aspiration and Biopsy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S303.	0.4	0
106	Bendamustine-Bortezomib-Dexamethasoneâ€‰in Heavily Pretreated Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S254-S255.	0.4	0
107	Pegfilgrastim versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S255-S256.	0.4	0
108	Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis. Blood, 2018, 132, 4290-4290.	1.4	0



#	ARTICLE	IF	CITATIONS
109	Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Blood</i> , 2018, 132, 5905-5905.	1.4	0
110	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Blood</i> , 2018, 132, 5648-5648.	1.4	0
111	Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease. <i>Blood Transfusion</i> , 2018, 16, 32-35.	0.4	0
112	Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma. <i>Annals of Hematology</i> , 2017, 96, 627-637.	1.8	45
113	A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 505-507.	0.5	3
114	Secondary syphilis mimicking malignancy: A case report and review of literature. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 576-578.	1.7	11
115	Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. <i>Cancer Medicine</i> , 2017, 6, 1500-1511.	2.8	14
116	Full Standard Doses of Lenalidomide in Bortezomib-Refractory Multiple Myeloma Patients Affected by Renal Failure: A Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S342-S343.	0.4	0
117	Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S343.	0.4	0
118	Front-Line Vascular Access Devices in Acute Leukemias – Peripherally Inserted Central Catheter (PICC) Versus Traditional Central Venous Catheter (CVC): A Phase IV Randomized Trial (NCT02405728). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S396-S397.	0.4	1
119	Lenalidomide at the Dose of Twenty-five mg Every Other Day in Patients Affected by Multiple Myeloma and Renal Failure: A Real-life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e122.	0.4	0
120	Bendamustine-Bortezomib-Dexamethasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e60-e61.	0.4	0
121	Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission. <i>Hematological Oncology</i> , 2017, 35, 311-311.	1.7	0
122	Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis. <i>Annals of Hematology</i> , 2017, 96, 697-699.	1.8	10
123	Reply to the letter to the editor –chronic disseminated candidiasis–by Kenneth Rolston. <i>Supportive Care in Cancer</i> , 2017, 25, 1045-1046.	2.2	0
124	Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. <i>Supportive Care in Cancer</i> , 2017, 25, 839-845.	2.2	20
125	The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. <i>Blood Cancer Journal</i> , 2017, 7, 649.	6.2	37
126	Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2017, 17, 105-110.	0.7	5



#	ARTICLE	IF	CITATIONS
127	Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. Case Reports in Hematology, 2016, 2016, 1-3.	0.4	4
128	Salvage therapy with pegylated liposomal doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.. European Journal of Haematology, 2016, 96, 544-544.	2.2	4
129	Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. Supportive Care in Cancer, 2016, 24, 4835-4837.	2.2	12
130	Randomized Comparison of Power Doppler Ultrasonography-Guided Core-Needle Biopsy with Open Surgical Biopsy for the Characterization of Lymphadenopathies in Patients with Suspected Lymphoma. Blood, 2016, 128, 685-685.	1.4	0
131	Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience. Blood, 2016, 128, 5713-5713.	1.4	0
132	18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. Clinical Nuclear Medicine, 2015, 40, 303-308.	1.3	30
133	208 MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE. Leukemia Research, 2015, 39, S104.	0.8	0
134	Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Supportive Care in Cancer, 2015, 23, 301-302.	2.2	13
135	Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Annals of Hematology, 2015, 94, 531-534.	1.8	12
136	P-187 Combination of deferasirox and deferoxamine in management of iron overload in myelodysplastic syndromes (MDS): An update in a hepatopatic patient. Leukemia Research, 2013, 37, S108.	0.8	0
137	P-165 Erythropoietic aspects in MDS patients responders to ESAs treatment. Leukemia Research, 2013, 37, S98.	0.8	0
138	Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Leukemia Research, 2009, 33, e104-e105.	0.8	9
139	An Innovative Organization&nbsp;&nbsp;&nbsp;Model to Face Risks Reduction Challenges in an Italian Cancer Center During the COVID-19 Pandemic: A Risk Reduction Estimation Study. SSRN Electronic Journal, 0, , .	0.4	0